# Schedules of Controlled Substances Placement June 02 2026 Updates > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/schedules-controlled-substances-placement-june-02-2026/ > **Published:** 2026-06-02T13:10:21-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:05:40-04:00 > **Clinical Summary:** Review the latest schedules of controlled substances placement June 02 2026, detailing DEA actions on synthetic cannabinoids and opioids impacting clinical practice. --- Policy WatchJune 02, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal Register [Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://www.federalregister.gov/documents/2026/04/24/2026-08104/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i) The DEA placed the synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting its legality and [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). [Read more →](https://www.federalregister.gov/documents/2026/04/24/2026-08104/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I](https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine) The DEA placed 3-Methoxyphencyclidine (3-MeO-PCP) into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use, impacting clinicians encountering similar dissociative substances. [Read more →](https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) The DEA temporarily placed bromazolam, a benzodiazepine sometimes found in unregulated cannabis products, into Schedule I, classifying it as having a high potential for abuse and no accepted medical use. [Read more →](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act](https://www.federalregister.gov/documents/2026/03/02/2026-04112/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and) The DEA placed five benzodiazepines—clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam—into Schedule I, impacting clinicians who may encounter patients using these substances concurrently with cannabis. [Read more →](https://www.federalregister.gov/documents/2026/03/02/2026-04112/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://www.federalregister.gov/documents/2026/01/20/2026-00954/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i) The DEA temporarily placed 2-Fluorodeschloroketamine in Schedule I, potentially impacting research and clinical use should this substance be considered alongside or as an alternative to [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). [Read more →](https://www.federalregister.gov/documents/2026/01/20/2026-00954/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I](https://www.federalregister.gov/documents/2026/01/15/2026-00633/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i) This action places 4-fluoroamphetamine in Schedule I, meaning it has a high potential for abuse and no currently accepted medical use, which may impact research involving similar chemical structures to [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/). [Read more →](https://www.federalregister.gov/documents/2026/01/15/2026-00633/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I](https://www.federalregister.gov/documents/2026/01/12/2026-00362/schedules-of-controlled-substances-placement-of-n-pyrrolidino-metonitazene-and-n-pyrrolidino) The DEA placed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, meaning these synthetic opioids have no accepted medical use and high abuse potential, potentially impacting differential diagnoses for clinicians. [Read more →](https://www.federalregister.gov/documents/2026/01/12/2026-00362/schedules-of-controlled-substances-placement-of-n-pyrrolidino-metonitazene-and-n-pyrrolidino) Score 70Federal Register [Schedules of Controlled Substances: Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I](https://www.federalregister.gov/documents/2025/12/23/2025-23717/schedules-of-controlled-substances-placement-of-n-desethyl-isotonitazene-and-n-piperidinyl) The DEA placed N-desethyl isotonitazene and N-piperidinyl etonitazene into Schedule I, impacting clinicians by restricting their use and potentially affecting patient access due to federal control. [Read more →](https://www.federalregister.gov/documents/2025/12/23/2025-23717/schedules-of-controlled-substances-placement-of-n-desethyl-isotonitazene-and-n-piperidinyl) Score 70Federal Register [Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I](https://www.federalregister.gov/documents/2025/12/16/2025-22963/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and) The DEA placed four synthetic cannabinoids into Schedule I, classifying them as having a high potential for abuse and no accepted medical use, impacting clinicians and patients encountering these substances. [Read more →](https://www.federalregister.gov/documents/2025/12/16/2025-22963/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://www.federalregister.gov/documents/2025/12/15/2025-22763/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) The DEA temporarily placed bromazolam, a benzodiazepine sometimes found in unregulated cannabis products, into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use in the US. [Read more →](https://www.federalregister.gov/documents/2025/12/15/2025-22763/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://www.federalregister.gov/documents/2025/12/11/2025-22495/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i) The DEA placed cumyl-pegaclone, a synthetic cannabinoid, into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use in the United States. [Read more →](https://www.federalregister.gov/documents/2025/12/11/2025-22495/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I](https://www.federalregister.gov/documents/2025/11/17/2025-20004/schedules-of-controlled-substances-placement-of-4-chloromethcathinone-in-schedule-i) The DEA placed 4-Chloromethcathinone in Schedule I, meaning it has a high potential for abuse and no currently accepted medical use, impacting clinicians assessing patient substance use. [Read more →](https://www.federalregister.gov/documents/2025/11/17/2025-20004/schedules-of-controlled-substances-placement-of-4-chloromethcathinone-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of Ethyleneoxynitazene, Methylenedioxynitazene, 5-Methyl Etodesnitazene, N-Desethyl Etonitazene, N-Desethyl Protonitazene, N,N-Dimethylamino Etonitazene, and N-Pyrrolidino Isotonitazene in Schedule I](https://www.federalregister.gov/documents/2025/10/15/2025-19542/schedules-of-controlled-substances-temporary-placement-of-ethyleneoxynitazene-methylenedioxynitazene) The DEA temporarily placed six synthetic opioids into Schedule I, impacting cannabis clinicians and patients through potential cross-contamination of unregulated products or misidentification as cannabis. [Read more →](https://www.federalregister.gov/documents/2025/10/15/2025-19542/schedules-of-controlled-substances-temporary-placement-of-ethyleneoxynitazene-methylenedioxynitazene) Score 70Federal Register [Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://www.federalregister.gov/documents/2025/10/02/2025-19348/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i) The DEA placed the synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting its legality and [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). [Read more →](https://www.federalregister.gov/documents/2025/10/02/2025-19348/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule I](https://www.federalregister.gov/documents/2025/09/18/2025-18103/schedules-of-controlled-substances-placement-of-seven-specific-fentanyl-related-substances-in) This DEA rule places seven fentanyl-related substances into Schedule I, potentially impacting clinicians evaluating patients with pain who may be considering or currently using these opioids alongside cannabis. [Read more →](https://www.federalregister.gov/documents/2025/09/18/2025-18103/schedules-of-controlled-substances-placement-of-seven-specific-fentanyl-related-substances-in) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I](https://www.federalregister.gov/documents/2025/08/15/2025-15566/schedules-of-controlled-substances-temporary-placement-of-n-pyrrolidino-metonitazene-and) The DEA temporarily placed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, impacting cannabis clinicians and patients due to potential misidentification or adulteration of products. [Read more →](https://www.federalregister.gov/documents/2025/08/15/2025-15566/schedules-of-controlled-substances-temporary-placement-of-n-pyrrolidino-metonitazene-and) Score 70Federal Register [Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act](https://www.federalregister.gov/documents/2025/07/25/2025-14022/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and) The DEA placed five benzodiazepines—clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam—into Schedule I, impacting clinicians who may encounter patients using these substances alongside cannabis. [Read more →](https://www.federalregister.gov/documents/2025/07/25/2025-14022/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and) Score 70Federal Register [Exempt Chemical Preparations Under the Controlled Substances Act](https://www.federalregister.gov/documents/2025/07/01/2025-12198/exempt-chemical-preparations-under-the-controlled-substances-act) The FDA clarified that certain hemp-derived cannabinoid products meeting specific criteria are exempt from the Controlled Substances Act, potentially impacting legal access for clinicians and patients. [Read more →](https://www.federalregister.gov/documents/2025/07/01/2025-12198/exempt-chemical-preparations-under-the-controlled-substances-act) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of Seven Benzimidazole-Opioids in Schedule I](https://www.federalregister.gov/documents/2025/06/26/2025-11462/schedules-of-controlled-substances-temporary-placement-of-seven-benzimidazole-opioids-in-schedule-i) The DEA temporarily placed seven synthetic opioids in Schedule I, potentially impacting research and access, though this action does not directly affect cannabis or its clinical use. [Read more →](https://www.federalregister.gov/documents/2025/06/26/2025-11462/schedules-of-controlled-substances-temporary-placement-of-seven-benzimidazole-opioids-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-[1-(3-methoxyphenyl)cyclohexyl]piperidine) in Schedule I](https://www.federalregister.gov/documents/2025/06/10/2025-10503/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine) The DEA placed 3-methoxyphencyclidine (3-MeO-PCP) into Schedule I, classifying it as having a high potential for abuse and no currently accepted medical use, which may impact research or clinical considerations involving similar substances. [Read more →](https://www.federalregister.gov/documents/2025/06/10/2025-10503/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine) Digest-Level Clinical Commentary Dr. Caplan’s Take Clinical Reflection As a [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practitioner, I observe that this digest consists almost entirely of synthetic [drug scheduling](https://cedclinic.com/controlled-substances-rescheduling-2026/) actions involving opioids, benzodiazepines, cathinones, and novel psychoactive substances, with no cannabis-specific scheduling changes among the 20 items listed. This pattern suggests that regulatory attention remains concentrated on addressing the emergence of illicit synthetic compounds and analogs rather than on cannabis plant material or its primary cannabinoids, which reflects the current regulatory landscape where cannabis scheduling differs fundamentally from these synthetic drugs despite ongoing federal classification. For my clinical practice, this underscores that [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) operates within a distinct regulatory framework shaped more by state-level legalization movements than by federal [drug scheduling](https://cedclinic.com/controlled-substances-rescheduling-2026/) actions, meaning my evidence-based prescribing decisions continue to depend primarily on state medical board guidance and evolving clinical literature rather than on federal scheduling changes Clinical Perspective These scheduling actions reflect the ongoing regulatory response to the proliferation of novel synthetic drugs designed to evade existing drug laws through minor chemical modifications. The majority of these substances are synthetic cannabinoids and novel opioids that have appeared in illicit drug supplies with increasing frequency, often associated with serious adverse effects and overdose deaths. The repeated scheduling of structurally similar compounds and the use of temporary scheduling authority suggest that clandestine manufacturers continue to outpace regulatory processes, necessitating rapid government response to emerging threats. Drug EnforcementSynthetic DrugsControlled SubstancesFederal Regulation 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Policy+Watch+%E2%80%94+June+02%2C+2026+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Policy+Watch+%E2%80%94+June+02%2C+2026+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-placement/) - [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) - [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/dea-synthetic-ketamine-analog-control-2-fdck-schedule-i/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Policy Watch: 20 Regulatory Updates — June 06, 2026](https://cedclinic.com/dea-synthetic-cannabinoids-schedule-i-june-2026/) Explore the regulatory updates following June 02, 2026, with detailed insights on controlled substances and synthetic cannabinoids. [Read More](https://cedclinic.com/dea-synthetic-cannabinoids-schedule-i-june-2026/) Policy Watch: 19 Regulatory Updates — June 16, 2026 Stay updated with the latest regulatory changes impacting controlled substances and cannabis-related policies in mid-June 2026. Explore Updates [Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I](https://cedclinic.com/dea-scheduling-benzodiazepine-analogs-schedule-i/) Detailed coverage of DEA scheduling actions on benzodiazepine analogs placed in Schedule I, relevant to clinicians and researchers. [Learn More](https://cedclinic.com/dea-scheduling-benzodiazepine-analogs-schedule-i/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).